Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 241 citing articles:

Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
Chiadi E Ndumele, Janani Rangaswami, Sheryl L. Chow, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1606-1635
Open Access | Times Cited: 310
Heart Failure With Preserved Ejection Fraction
Barry A. Borlaug, Kavita Sharma, Sanjiv J. Shah, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 18, pp. 1810-1834
Open Access | Times Cited: 220
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention
Nathan D. Wong, Naveed Sattar
Nature Reviews Cardiology (2023) Vol. 20, Iss. 10, pp. 685-695
Closed Access | Times Cited: 156
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
Milton Packer
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 443-462
Open Access | Times Cited: 90
SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Khawaja M. Talha, Stefan D. Anker, Javed Butler
International Journal of Heart Failure (2023) Vol. 5, Iss. 2, pp. 82-82
Open Access | Times Cited: 66
Ketones and the Heart: Metabolic Principles and Therapeutic Implications
Timothy Matsuura, Patrycja Puchalska, Peter A. Crawford, et al.
Circulation Research (2023) Vol. 132, Iss. 7, pp. 882-898
Open Access | Times Cited: 66
Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction
Carlos G. Santos‐Gallego, Juan Antonio Requena-Ibáñez, Belén Picatoste, et al.
Circulation Cardiovascular Imaging (2023) Vol. 16, Iss. 4
Closed Access | Times Cited: 56
Metabolic Communication by SGLT2 Inhibition
A. Billing, Young Chul Kim, Søren Gullaksen, et al.
Circulation (2023) Vol. 149, Iss. 11, pp. 860-884
Open Access | Times Cited: 52
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Pierre Gourdy, Patrice Darmon, François Diévart, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 51
Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial
Barry A. Borlaug, Yogesh N.V. Reddy, A Braun, et al.
Circulation (2023) Vol. 148, Iss. 10, pp. 834-844
Open Access | Times Cited: 50
SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy
Xinyu Zhao, Shuangshuang Li, Ying-xin He, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 10, pp. 1328-1340
Closed Access | Times Cited: 48
Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes
Milton Packer, Christopher S. Wilcox, Jeffrey M. Testani
Circulation (2023) Vol. 148, Iss. 4, pp. 354-372
Open Access | Times Cited: 45
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
Ellen M. Apperloo, Brendon L. Neuen, Robert A. Fletcher, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 8, pp. 545-557
Open Access | Times Cited: 35
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 27
Polyphenols: immunonutrients tipping the balance of immunometabolism in chronic diseases
Carolina Ferreira, Pedro Vieira, Susana Machado, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 20
Acute antiarrhythmic effects of SGLT2 inhibitors–dapagliflozin lowers the excitability of atrial cardiomyocytes
A Paasche, Felix Wiedmann, Manuel Kraft, et al.
Basic Research in Cardiology (2024) Vol. 119, Iss. 1, pp. 93-112
Open Access | Times Cited: 17
Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity
Naveed Sattar, Calum Presslie, Martin K. Rutter, et al.
Diabetes Care (2024) Vol. 47, Iss. 4, pp. 531-543
Open Access | Times Cited: 16
Sirtuins in kidney health and disease
Luca Perico, Giuseppe Remuzzi, Ariela Benigni
Nature Reviews Nephrology (2024) Vol. 20, Iss. 5, pp. 313-329
Closed Access | Times Cited: 15
Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice
Sara Ranjbarvaziri, Aliya Zeng, Iris Wu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
Mohamed S. Dabour, Mina Y. George, Mary R. Daniel, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 2, pp. 159-182
Open Access | Times Cited: 15
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Research progress on Sirtuins (SIRTs) family modulators
Mingkai Chen, Junfei Tan, Zihan Jin, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116481-116481
Open Access | Times Cited: 14
SGLT2i Therapy Prevents Anthracycline-Induced Cardiotoxicity in a Large Animal Model by Preserving Myocardial Energetics
Danielle Medina-Hernández, Laura Cádiz, Annalaura Mastrangelo, et al.
JACC CardioOncology (2025) Vol. 7, Iss. 2, pp. 171-184
Open Access | Times Cited: 1
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 34
Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors
Milton Packer
European Heart Journal (2023) Vol. 44, Iss. 48, pp. 5027-5035
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top